Sinda Ltd (SIND) News & EventsSINDSinda Ltd

Sinda Files to Sell 7.94M Shares of Common Stock

Sinda files to sell 7.94M shares of common stock for holders

Sinda, DPC Holdings, and DSC Holdings Successfully Debut in IPOs

A handful of deals opened last week across metals exploration, aerospace components, and AI infrastructure, with Sinda, DPC Holdings, and DSC Holdings all making their market debuts.LATEST IPOS AND DIRECT LISTINGS:Sindaopened on June 26 at $10.80. The company priced 17.75M shares at $12.00, inside the $11.25-$13.25 target range. Sinda, a silver exploration company with mineral projects in Mexico.DPC Holdingsopened on June 25 at $44.00. The company priced 27.86M shares at $33.00. The deal size was increased to 27.86M shares from 23.3M and priced above the $28.00-$32.00 range. DPC Holdings, doing business as Doncasters, is an independent manufacturer of complex, highly engineered precision cast components and nickel- and cobalt-based superalloys primarily serving the high growth Aerospace and IGT end markets.DSC Holdingsopened on June 25 at $16. The company priced its initial public offering of 3M American depositary shares at $17 per ADS. The deal priced at the midpoint of the $16.00-$18.00 target range. DSC offers AI application infrastructure for China's used car industry.RECENT SPAC IPOS:Alpex Acquisitionopened on June 25 at $10.01. Alpex is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.Cartesian Growth Corporation IVopened on June 25 at $9.95. Cartesian is a blank check company organized for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.Gores Holdings XIopened on June 23 at $10.05. Santander is acting as the sole underwriter for the offering.PERFORMANCE:Prices as of 10.45 am ET on Monday, June 29Sinda – fractionally up at $12.03;DPC Holdings – up almost 3% at $48.44;DSC Holdings – down about 4% at $6.97.RECENT IPOS TO WATCH:Quantinuum, Innio, Sunshine Silver Mining & Refining, Applied Aerospace & Defense, and Liftoff Mobileare already seeing coverage roll out as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Bending Spoons, Kardigan, Inspire Brands, and Tarsier Pharma.Clickto see upcoming IPO calendar on TipRanks.Bending Spoons, a technology company whose main businesses include AOL, Brightcove, Eventbrite, Evernote, Harvest, komoot, Remini, StreamYard, Vimeo, and WeTransfer, announces that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The timing of the offering, number of shares to be offered, and the price range for the proposed offering have not yet been determined. Bending Spoons has applied to list its ordinary shares on the Nasdaq Global Select Market under the ticker symbol "BSP."Kardiganhas filed an initial public offering of shares of its common stock. The company has applied to list its common stock on the Nasdaq Global Market under the symbol "KARD." JP Morgan, Jefferies, Leerink Partners, and TD Cowen are acting as the underwriters for the offering.Inspire Brandsannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. Inspire Brands expects to use the net proceeds of the proposed offering to repay outstanding indebtedness under its existing term loan facility and pay offering fees and expenses.Tarsier Pharma Ltd.filed for an initial public offering of its ordinary shares and applied to list its ordinary shares on the NYSE American under the symbol "TARX". The prospectus stated: "Tarsier Pharma is developing TRS01 and TRS02, novel product candidates based on dazdotuftide, a new molecule with a new mechanism of action for uveitis and uveitic glaucoma. We are attempting to address a significant, underserved market opportunity and have engaged closely with the FDA on our clinical development strategy, including a Special Protocol Assessment agreement for our planned pivotal trial... Although we are still early in this journey, I believe we have the technology, the team, the discipline, and the persistence required to build an enduring company."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.